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ABSTRACT 
Drug use evaluation is an on-going, systematic, criteria-based program of medicine evaluations that will help ensure appropriate medicine use. 
If therapy is determined to be inappropriate, interventions with providers or patients will be necessary to optimize pharmaceutical therapy. In 
our study we have developed a data collection form based upon WHO guidelines for conducting a DUE study on metronidazole use evaluation. 
To assess the usage of metronidazole at a tertiary care center Hyderabad a retrospective evaluation of usage patterns was carried out for the 
period of 6 months corresponding to the dates to 1-1-2018 to 30-6-2018. For conducting the evaluation process we had followed the standard 
guide lines formulated by WHO. The gender distribution of case sheets were male- 69, female- 80. Indication wise the distribution of case sheets 
were -43.23% are prophylaxis and surgical prophylaxis, 32.81% are non-indicated and 18, 96% were given for infections. The minimum 
number of days of treatment was 1 day and the maximum number of days of treatment was 23 days. All patient folders evaluated with regards 
to cellulitis, gynaecological surgeries, UTI, LRTI etc were found to meet the standard criteria appropriate for metronidazole use with respect to 
dose, and dose frequency. However, in the case of duration the evaluation was found to be largely inappropriate for all the j ustified indications. 
In addition, 34.81% of metronidazole use for unjustified indications was noted. This means that metronidazole has been deviated from 
standard treatment guidelines hence it facilitates the development of resistant strains to metronidazole and of no use in the near future, and it 
also affect the patient economically. 
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INTRODUCTION  
Drug use evaluation is an ongoing, systematic, criteria-based 
program of medicine evaluations that will help ensure 
appropriate medicine use. If therapy is determined to be 
inappropriate, interventions with providers or patients will 
be necessary to optimize pharmaceutical therapy. A DUE can 
be structured so that it will assess the actual process of 
administering or dispensing a medicine (i.e., appropriate 
indications, dose, medicine interactions) or assess the 
outcomes. The following eight steps outline the basic 
information necessary to start and maintain a DUE Program. 
Establish Responsibility: Responsibility falls to the DTC or 
a subcommittee of the DTC that functions only to monitor 
DUEs In the hospital or clinic. The DTC should undertake this 
responsibility with considerable interest, because this 
process can solve many medicine use problems, as has 
proven to be the Case in many countries where this quality 
assurance function has been fully utilized. The DTC or a 
subcommittee must establish procedures that will govern 
the committee in its activities concerning medicine use 
review and evaluation. As part of the responsibility of the 
DUE function, the DTC must establish a plan, outlining which 
medicines will be a part of the DUE process. This plan needs 
to be updated and evaluated each year. 
Develop Scope of Activities 
 The DTC should assess and identify medicine use problems 
and using this information to develop a scope of activity for 
the DUE program. The scope can be extensive, or it can focus 
on a single aspect of pharmaceutical therapy. Methods to 
identify medicine use problems include and ABC or vital, 
essential, nonessential (VEN) analysis, defined daily dose 
analysis, ADR reports, medication error reports, antibiotic 
sensitivity results, procurement studies, hospital and 
primary care clinic indicator studies, patient complaints or 
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feedback, and staff feedback. These screening mechanisms 
serve to provide the DTC with information concerning 
medicine use that would need further evaluation in a DUE. 
Establish Criteria, Define and Establish Thresholds 
Criteria are statements that define correct medicine use. 
Establishing criteria is the single most important procedure 
in a DUE. Criteria for the use of any medicine should be 
established by the DTC using relevant evidence based 
literature sources and recognized international and local 
experts. The criteria for any DUE should reflect what is in the 
country’s STGs (assuming that they have been developed 
correctly) and any medicine-use protocols that exist. 
Credibility of the DUE relies on criteria that are based on 
evidence-based medicine. Criteria must be developed with 
and accepted by the medical staff for the process to be 
credible. Criteria should be developed for three to five of the 
most important indicators for each aspect of medicine use. 
Reviewing larger numbers of indicators will make for a more 
difficult DUE process and may significantly impair the 
outcomes of the review. This is not to say that more 
extensive use of indicators should not be reviewed; only that 
results are more easily obtained and possibly more 
meaningful when the scope is narrowed to include only the 
most Important aspects of care. After developing criteria, the 
DTC must establish a threshold or standard (benchmark) 
against which the criteria will be judged. A threshold refers 
to the percentage of charts or records that will meet or 
exceed the established criteria for the medicine. Ideally, this 
threshold will be 100 percent, but realistically, a smaller 
percentage will be more appropriate to account for 
exceptions to routine medicine prescribing. Therefore, a 
threshold of 90 to 95 percent is typically used for many 
criteria, but each instance must be carefully analyzed before 
reaching a conclusion. 
Collect Data and Organize Results. 
 DUEs can be accomplished as prospective evaluations, or 
they can be performed retrospectively. A prospective 
analysis involves the collection of data as the medicine is 
being prepared or dispensed to the patient. Retrospective 
analysis is done using chart reviews or other data sources to 
review medicine use according to indicators and criteria 
prepared in advance. The advantage of a prospective review 
is that the pharmacist (or other reviewer) can intervene at 
the time the medicine is dispensed to prevent errors in, for 
example, dosage, indications, or interactions. Retrospective 
evaluation, which may involve more of the reviewer’s time or 
require access to medical records, is best accomplished when 
the reviewer has time away from the patient care areas and 
distractions. 
Analyze Data  
Data are collected, tabulated, and analyzed to see if criteria 
and thresholds are met. The following important steps 
should be completed when analyzing data— 
• Tabulate results for each indicator 
• Analyze results to see if the criteria are met and the 
thresholds are not exceeded 
• Determine why thresholds are not met 
• Analyze data quarterly or more frequently 
If a threshold is not met, it may indicate a medicine use 
problem that requires the attention of the DTC. 
Develop Recommendations and Action Plan  
After completing the data analysis, information is presented 
to the DTC and a decision is made as to the appropriateness 
of the information in the DUE. The DTC also must decide on 
whether to continue, discontinue, or expand the functions of 
the DUE in question. All medicines that do not meet the 
thresholds must be evaluated carefully and plans must be 
made to improve the use of the medicine relative to the 
criteria. 
Recommendations should be prepared for the DTC to 
address the following— 
• Inappropriate medicine use 
• Unacceptable patient outcomes 
• Methods to resolve any medicine use problem 
Recommendations should include specific steps to correct 
any medicine use problem that is evident from performing 
the DUE. For example, if a specific medicine is being 
prescribed at a high dose, then the recommendations need to 
reflect this and how the DTC might improve the dosing of 
this medicine. Interventions to improve medicine use might 
include— 
• Education, including letters to practitioners, in-service 
education, workshops, newsletters, and faceto-face 
discussions 
• Implementation of medicine order forms 
• Prescribing restrictions 
• Formulary manual changes 
• Change (or better enforcement) of the STGs. 
Conduct DUE Follow-up  
Follow-up in every DUE is critical to ensure resolution of any 
unresolved medicine use problems. The DUE may have 
identified new problems that need to be resolved within the 
health care system. If the problems are not resolved, then the 
DUE will have little usefulness to the health care system. As a 
part of a follow-up plan, the DTC must assess the need to 
continue, modify, or stop the DUE activity depending on the 
results of each specific medicine review. A DUE should be an 
on-going process in which medicine related problems are 
regularly addressed. Medicine review should be considered a 
long-term program, one that is continuously updated and 
revised to reflect current situations and needs within the 
health care institution. All programs within the DTC should 
be evaluated yearly. This complete evaluation is necessary to 
look comprehensively at the entire program and analyze its 
merits and its utility in improving medicine use. Programs 
that do not have a significant impact on medicine use should 
be redesigned so that they can provide measurable 
improvements. Without improvements in medicine use and 
patient outcomes, the time spent on DUE will be of no value. 
It must be stressed that indicators and criteria for a DUE can 
be highly individualized depending on the specific needs of 
the health care facility.[1,2] 
Metronidazole: 
Metronidazole, a nitroimidazole, exerts antibacterial effects 
in an anaerobic environment against most obligate 
anaerobes. Once metronidazole enters the organism by 
passive diffusion and is activated in the cytoplasm of 
susceptible anaerobic bacteria, it is reduced; this process 
includes intra-cellular electron transport proteins such as 
ferredoxin, transfer of an electron to the nitro group of the 
metronidazole, and formation of a short-lived nitroso free 
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radical. Because of this alteration of the metronidazole 
molecule, a concentration gradient is created and maintained 
which promotes the drug’s intracellular transport. The 
reduced form of metronidazole and free radicals can interact 
with DNA leading to inhibition of DNA synthesis and DNA 
degradation leading to death of bacteria. The precise 
mechanism of action of metronidazole is unclear. 
Metronidazole Indications: 
Metronidazole is indicated in the following conditions: 
Treatment of Anaerobic Bacterial Infections 
Metronidazole Injection, USP is indicated in the treatment of 
serious infections caused by susceptible anaerobic bacteria. 
Indicated surgical procedures should be performed in 
conjunction with Metronidazole Injection, USP therapy. In a 
mixed aerobic and anaerobic infection, antibiotics 
appropriate for the treatment of the aerobic infection should 
be used in addition to Metronidazole Injection, USP. 
Metronidazole Injection, USP is effective in Bacteroides 
fragilis infections resistant to clindamycin, chloramphenicol 
and penicillin.  
Intra-Abdominal Infections, including peritonitis, intra-
abdominal abscess and liver abscess, caused by Bacteroides 
species including the B. fragilis group (B. fragilis, B. 
distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), 
Clostridium species, Eubacterium species, Peptococcus 
species and Peptostreptococcus species.  
Skin and Skin Structure Infections caused by Bacteroides 
species including the B. fragilis group, Clostridium species, 
Peptococcus species, Peptostreptococcus species and 
Fusobacterium species. Gynecologic Infections, including 
endometritis, endomyometritis, tubo-ovarian abscess and 
postsurgical vaginal cuff infection, caused by Bacteroides 
species including the B. fragilis group, Clostridium species, 
Peptococcus species, Peptostreptococcus species and 
Fusobacterium species.  
Bacterial Septicemia caused by Bacteroides species 
including the B. fragilis group and Clostridium species. Bone 
and Joint Infections, as adjunctive therapy, caused by 
Bacteroides species including the B. fragilis group. 
Central Nervous System (CNS) Infections, including 
meningitis and brain abscess, caused by Bacteroides species 
including the B. fragilis group.  
Lower Respiratory Tract Infections, including pneumonia, 
empyema and lung abscess, caused by Bacteroides species 
including the B. fragilis group. Endocarditis caused by 
Bacteroides species including the B. fragilis group.  
Prophylaxis: The prophylactic administration of 
Metronidazole Injection, USP preoperatively, 
intraoperatively and postoperatively may reduce the 
incidence of postoperative infection in patients undergoing 
elective colorectal surgery which is classified as 
contaminated or potentially contaminated. Prophylactic use 
of Metronidazole Injection, USP should be discontinued 
within 12 hours after surgery. If there are signs of infection, 
specimens for cultures should be obtained for the 
identification of the causative organism(s) so that 
appropriate therapy may be given. To reduce the 
development of drug-resistant bacteria and maintain the 
effectiveness of Metronidazole Injection, USP and other 
antibacterial drugs, Metronidazole Injection, USP should be 
used only to treat or prevent infections that are proven or 
strongly suspected to be caused by susceptible bacteria. 
When culture and susceptibility information are available, 
they should be considered in selecting or modifying 
antibacterial therapy. In the absence of such data, local 
epidemiology and susceptibility patterns may contribute to 
the empiric selection of therapy. 
Dose and Administration: 
Dosage, rate of administration, and duration of treatment are 
to be individualized and depend upon the indication for use, 
the patient’s age, weight, clinical condition and concomitant 
treatment, and on the patient’s clinical and laboratory 
response to the treatment. 
Loading Dose: 15 mg/kg infused intravenously over one 
hour (approximately 1 gram for a 70-kg adult). 
Maintenance Dose: 7.5 mg/kg infused intravenously over 
one hour every six hours (approximately 500 mg for a 70-kg 
adult). The first maintenance dose should be instituted six 
hours following the initiation of the loading dose.[3] 
Aim and objectives: 
Aim: To assess the usage of metronidazole at a tertiary care 
hospital in Hyderabad compared to the indications for 
metronidazole use and standard treatment guidelines and 
provide recommendations to improve rational use of 
metronidazole at these hospitals  and reduce the 
development of further antibiotic resistance, prevent ADRs 
associated with the drug, and to reduce the economic burden 
on the patient with inappropriate use. 
Objectives: 
 To analyse the pattern of metronidazole use among 
patient categories identified by age.  
 To identify the illnesses most frequently treated with 
metronidazole 
 To determine whether metronidazole was appro-
priately prescribed in respect of dose, dose frequency, 
and dose duration.  
 To identify areas in which further information and 
education was needed by health care provider.  
 To evaluate reason for stopping (discontinue)the drug 
is based on guide line or not.  
 To assess whether the indication of metronidazole  is 
on par with standard guidelines or not. 
 To assess the frequency of ADRs associated with the 
drug use. 
 To assess the potential and actual Drug-Drug 
interactions associated with metronidazole. 
MATERIALS AND METHODS 
Study Design: Retrospective Drug Utilization Evaluation 
Study. 
Study Site: A tertiary Care Center at Hyderabad {Gandhi 
Hospital}, India. 
Study Duration: 6 months. 
Source of Data: A Data-collection form was developed based 
on WHO Guidelines. 
Sample Size: 149. 
Study Procedure: Since it is a retrospective study, we have 
collected all the case records from the medical record 
department from   1-01-2018 to 30-6-2018 that contained 
metronidazole in the prescription. A total of 149 case records 
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were obtained containing metronidazole as a drug in the 
prescription. During the process of evaluation, the 
prescriptions were analyzed for correct indication, correct 
dose, frequency, ADRs, Drug-Drug interactions, and contra-
indications. The criteria established were adopted from 
standard treatment guidelines as formulated by FDA. The 
Threshold was developed by taking into consideration; the 
prescribing habits (KAP) of the doctors at these centers, the 
indicators are assigned with a threshold of 90-100%. 
Study Design: 
 A retrospective evaluation of metronidazole usage patterns 
was carried out at a tertiary care hospital for the period of 6 
months corresponding to the dates to 1-1-2018 to 31-6-
2018. 
 For conducting the evaluation process we had followed the 
standard guide lines formulated by WHO. 
 
Step 1 : Responsibility 
The hospital where the study was conducted doesn’t have 
DTCs and moreover the study is for academic purposes and 
hence the responsibility lied entirely with the students and 
guide. 
Step 2.  Scope of Activities 
During the process of evaluation, the prescriptions were 
analyzed for correct indication, correct dose, frequency, 
ADRs, Drug-Drug interactions, and contra-indications.  
Step 3.Criteria 
Standard prescribing guidelines for metronidazole as 
formulated by FDA. 
Step 4. Establishing Threshold 
Taking into consideration, the prescribing habits (KAP) of 
the doctors at these centres, the indicators are assigned with 
a threshold of 90-100%.  
 
Indicator  Criteria Threshold% 
Indication PO, IV: Treatment of the following anaerobic infections: Intra-abdominal infections (may be 
used with a cephalosporin), Gynecologic infections, Skin and skin structure infections, 
Lower respiratory tract infections, Bone and joint infections, CNS infections, Septicemia, 
Endocarditis. IV Perioperative prophylactic agent in colorectal surgery. PO: Amebicide in 
the management of amebic dysentery, amebic liver abscess, and trichomoniasis: Treatment 
of peptic ulcer disease caused by Helicobacter pylori. Topical Treatment of acne rosacea. 
Vag:Management of bacterial vaginosis. Unlabeled Use: Treatment of giardiasis. Treatment 
of anti-infective associated pseudomembranous colitis. 
90% 
 
Dose and 
frequency and 
duration 
PO (Adults): Anaerobic infections—7.5 mg/kg q 6 hr (not to exceed 4 g/day). 
Trichomoniasis—250 mg q 8 hr for 7 days orsingle 2-g dose or 1 g twice daily for 1 day. 
Amebiasis—500– 750 mg q 8 hr for 5– 10 days. H. pylori—250 mg 4 times daily or 500 mg 
twice daily for 1– 2 wk (with other agents). Bacterial vaginoses— 750 mg once daily as ER 
tablets for 7 days. Antibiotic associated pseudomembranous colitis—250– 500 mg 3– 4 
times/day for 10– 14 days. PO (Infants and Children): Anaerobic infections—30 
mg/kg/day divided q 6 hr, maximum dose: 4 g/day Trichomoniasis—15– 30 mg/kg/day 
divided q 8 hr for 7– 10 days. Amebiasis—35– 50 mg/kg/day divided q 8 hr for 5– 10 days 
(not to exceed 750 mg/dose). Antibiotic associated pseudomembranous colitis—30 mg/ 
kg/day divided q 6 hr for 7– 10 days. H. pylori—15– 20 mg/kg/day divided twice daily for 
4 weeks. IV, PO (Neonates 0– 4 weeks, 1200 g): 7.5 mg/kg q 48 hr. Postnatal age 7 days, 
1200– 2000 g—7.5 mg/kg/day q 24 hr. Postnatal age 7 days, 2000 g— 15 mg/kg/day 
divided q 12 hr. Postnatal age 7 days, 1200– 2000 g—15 mg/kg/ day divided q 12 hr. 
Postnatal age 7 days, 2000 g—30 mg/kg/day divided q 12 hr. IV (Adults): Anaerobic 
infections—Initial dose 15 mg/kg, then 7.5 mg/kg q 6– 8 hr or 500 mg q 6– 8 hr (not to 
exceed 4 g/day). Perioperative prophylaxis—Initial dose 15 mg/kg 1 hr before surgery, 
then 7.5 mg/kg 6 and 12 hr later. Amebiasis— 500– 750 mg q 8 hr for 5– 10 days. IV 
(Children): Anaerobic infections—30 mg/kg/day divided q 6 hr, maximum dose: 4 g/day. 
Topical (Adults): Acne rosacea—Apply thin film to affected area bid. Vag (Adults): Bacterial 
vaginosis—One applicatorful (5 g) 2 times daily for 5 days. 
95% 
 
contraindicatio
ns 
Contraindicated in: Hypersensitivity; Hypersensitivity to parabens (topical only); OB:First 
trimester of pregnancy. Use Cautiously in: History of blood dyscrasias; History of seizures 
or neurologic problems; Severe hepatic impairment (dosepsuggested); OB: Although safety 
not established, has been used to treat trichomoniasis in 2nd- and 3rd-trimester 
pregnancy— but not as single-dose regimen; Lactation: If needed, use single dose and 
interrupt nursing for 24 hr thereafter; Patients receiving corticosteroids or predisposed to 
edema (injection contains 28 mEq sodium/g metronidazole). 
       100% 
Drug 
Interaction 
Drug-Drug: Cimetidine may ↓ metabolism. Phenobarbital and rifampin may ↑ metabolism 
and may ↓ effectiveness. Metronidazole ↑ the effects of phenytoin, lithium, and warfarin. 
Disulfiram-like reaction may occur with alcohol ingestion. May cause acute psychosis and 
confusion with disulfiram  ↑ risk of leukopenia with fluorouracil or azathioprine. 
 
90% 
 
Outcome  Negative culture/Improved symptomatology 
No treatment failure 
 90%       
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Step 5. Data collection and organisation. 
The data was collected in data collection forms and 
organised according to the threshold percentage. 
A total of 149 case sheets  were obtained that contained 
metronidazole in the prescription between the period of 1-1-
2018 to 30-6-2018. 
Step 6.Data analysis. 
The data obtained was analysed. 
Step 7.Develop recommendations and Action plan. 
Based on the results obtained, problematic areas were 
identified and appropriate recommendations were 
developed and shared with the concerned doctors and 
hospital authorities. 
RESULTS AND DISCUSSION 
This study provides the data on the use of metronidazole at a 
tertiary care Gandhi hospital. The considered parameters 
are age, gender, indication, dose, frequency, duration of 
therapy, contraindications and drug interacting with 
metronidazole. 
Drug utilization pattern according to gender: 
A total of 149 cases of metronidazole use were identified 
between the period from 1/1/18 - 30/6/18 patient. The 
distribution of cases on gender basis is  69 males (46.31%) 
and 80 females (53.69%). 
Drug utilization pattern according to age: 
The age range was between 4 months and 85 years. The 
usage pattern of metronidazole among various age groups 
are as follows:  of 0-10 (2.013%), 11-20 (3.355%),  21-30yrs 
(17.449%) and 31-40 (24.832%), 41-50 (19.46%), 51-60 
(24.16%), 61-70 (7.38%),  71-80 (0%),  81-90 (0.671%) and   
91-100 (0%). 
As per STGs, the percentage of metronidazole used (21%) 
was non indicated and it has’nt met the established criteria, 
and the rest used for infections (18.76%) , 
prophylaxis(28.75) and surgical prophylaxis(31.49)  met the 
criteria. 
Drug utilization pattern according to indication: 
In our study, the percentage of metronidazole indicated in 
the conditions are :- 
Infections: 
urinary tract infections-2 (1.34%), cellulitis -4 (2.684%), 
pneumonitis -2 (1.34%), pseudocyst -4 (2.68%), liver 
abscess -5 (3.35%), schistomiasis -1 (0.67%), gastroenteritis 
-2 (1.34%), breast abscess -1 (0.67%), peritonitis -2 
(1.34%), diarrhea -1 (0.67%), placenta infected -1 (0.67%), 
wound infection -1 (0.67%), acid peptic ulcer-1 (0.67%), 
infective endocarditis-1 (0.67%). 
Diseases Not Indicated In Standard Guidelines: 
fibroid uterus -7 (4.69%), postmenopausal bleeding -1 
(0.67%), anemia -2 (1.34%), cystocele, 
rectocele,enterocele,hydrocele, meningocele -1 (0.67%), 
diabetic nephropathy -1 (0.67%), CKD – acute deterioration 
-6 (4.02%), AKI with CKD -6 (4.02%), uremic 
encephalopathy -6 (4.02%), bladder outlet obstruction -2 
(1.34%), obstructive uropathy -2 (1.34%), retinopathy -4 
(2.684%), febrile illness-2 (1.34%), thrombocytopenia-2 
(1.34%), acute pancreatitis-3 (2.01%), chronic pancreatitis -
7 (4.69%) , UTI bleed -2 (1.34%), oesophageal varies -3 
(2.01%), ald -5 (3.35%), distal cbd -4 (2.684%), hepatic 
encephalopathy -2  (1.34%), ascites -4 (2.684%), portal 
hypertension-1 (0.67%), sigmoid diverticulitis -1 (0.67%), 
stomach ulcer  -1 (0.67%), cld-1 (0.67%), supra condylar 
femur -1 (0.67%), pulmonary tb -1 (0.67%). 
Prophylaxis: 
septicemia -1 (0.67%), cva-2 (1.34%), status post adjunct 
chemotherapy -2 (1.34%), blood transfusion -4 (2.684%), 
sepsis -7 (4.69%), renal biopsy-1(0.67%), ijv catheter -7 
(4.69%), hemodialysis -8 (5.3%), pd catheter -7 (4.69%), 
paraurethral tear after delivery -1 (0.67%), uteroplacental 
insufficiency -1 (0.67%), after delivery -2 (1.34%). 
Post-Operative Prophylaxis 
Laproscopic cystectomy -4 (2.684%), Myomectomy -4 
(2.684%), Total abdominal hysterectomy -7 (4.69%), Lt 
bartollins cyst excision -2 (1.34%), Laparoscopic assisted 
vaginal hysterectomy (LAVH) -4 (2.684%), Pelvic floor 
repair -1 (0.67%), Dilation and curettage -2 (1.34%), 
Salpingoophorectomy -5 (3.35%), Infracolic oomentectomy -
1 (0.67%), Salpingectomy -4(2.684%), ,Vaginoplasty -
1(0.67%) , Tubal recanalisation -1 (0.67%), Laparoscopic 
surgery -1 (0.67%), Tubectomy -1 (0.67%), Laparatomy -1 
(0.67%), Episiotomy –1 (0.67%),LSCS -1 (0.67%), 
Polypectomy -1 (0.67%), Laparoscopic ectopic resection -1 
(0.67%), Marsupialization -1 (0.67%), Percutaneus 
nephrotomy -3 (2.01%), Appendectomy -1 (0.67%), 
Cystolithiomy -1 (0.67%), EVL-4 (2.684%) 
Splenectomy -1(0.67%,ERCP+ biliary stent placement -1 
(0.67%), Portosystemic shunt -1 (0.67%), Liver 
transplantation -1 (0.67%), Renal transplantation -1 
(0.67%), Gastrectomy -1 (0.67%), Hemicolectomy -1 
(0.67%), Papilotomy –ERCP -1 (0.67%), Cholecystectomy-1 
(0.67%), Excision and repair meningocele -1 (0.67%). 
Drug utilization pattern according to dose, ROA, Frequency, 
and the potential for interaction  
In this research, the criteria of appropriateness of 
metronidazole use at the dose, dose frequency, dose 
duration were 
The dose of metronidazole based on indication and duration 
given was 100ml/500 mg  IV TID & 400mg oral TID .In all 
the indications studied, they met the benchmark 
requirement of 95%. Therefore metronidazole was used 
appropriately so far as dose was concerned. 
Out of 149 cases, dose frequencies were eight hours and 
twenty four hours in 3cases(2.01%) and 146 cases(97.98%) 
respectively. 
Dose, durations were mostly inappropriate for all the 
justified indications studied.  
i.metronidazole is given more than thershold limit  36 
ii.metronidazole is given according to thershold limit 34 
iii.metronidazole is given less than thershold limit 79 
 
Drug Interactions: 
Metronidazole has interacted with a variety of 
concomitantly administered drugs- 
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Clarithryomycin 0.67% 
Ondansetron 10.70% 
Tramadol 27.50% 
Ciprofloxacin 11.40% 
Efavirenz 0.67% 
Ofloxacin 26.80% 
Atorvastatin 2.01% 
Terlipressin 2.01% 
Hydroxyzine 1.34% 
Secnidazole 0.67% 
without interactions 26.18% 
 
Culture and Sensitivity Test: 
As per standard guidelines culture test is necessary to 
promote rationalize drug therapy. In gastroenterology 
department out of 41 cases only (7.31%) 3 cases have done 
with the test. In gynecological department no test has been 
performed. In nephrology department  out of 36 cases only 
(2.71%) 1 case done with the test. In general medicine no 
test has been performed. 
Reason for Ceasing Metronidazole: 
Discharge with other class of antibiotic (12.08%), course 
completed (48.99%), change to narrow agent (20.13%), 
organism resistant(10.73%), patient expired(4.02%), 
patient discharge with metronidazole(1.34%), culture –
ve(2.68%). 
Drug utilization pattern according to contraindications: 
As per STGs, metronidazole is contraindicated in first 
trimester of pregnancy. In our study, out of 149 cases, 
149cases are met threshold according to STG’s. 
Outcomes: 
34.84% of the cases received metronidazole for non-
indications, 24% of the cases are without interactions, 
22.81% met the threshold for duration of therapy, 10.02% 
cases have undergone culture sensitivity test. 
Metronidazole is a broad spectrum antibiotic belongs to 
class nitroimidazoles. Now a days metronidazole is 
irrationally prescribed globally particularly in India. Hence it 
facilitates the development of resistant strains to 
metronidazole. And is more prone to cause complications 
(ADR’s) like asceptic meningitis, encephalopathy, seizures 
and common symptoms like headache, dizziness, abdominal 
pain, anorexia it is not usually indicated in pregnancy except 
in life threatening conditions.  
Threats of resistance development to metronidazole 
The development of resistance by microorganisms is of 
global concern. This is because microorganisms that were 
susceptible to some anti-infective agents have now become 
resistant. Unfortunately, irrational prescribing is a global 
problem. Studies on medicine prescribing in India have 
concluded that much of it is irrational. Making a prescribing 
decision is vital in the prevention of morbidity and mortality. 
The physician’s prescribing decision is the result of input 
from patients, commercial sources, professional colleagues, 
academic literature, and government regulations. Ineffective 
use of these sources of information can result in a wide 
variety of prescribing errors. Medicine utilization review is 
the most common and structured approach used to examine 
patterns of medicine use and to determine levels of 
appropriateness in prescribing. Medicine usage reviews are 
essential in order to establish the extent of rational and 
irrational prescribing and to deliver better healthcare 
services. Antimicrobials, like any other medicines, may be 
used inappropriately.  
A prescriber may choose an inappropriate type of 
antimicrobial, taking into account the clinical condition, 
resistance patterns and cost. Continuing antimicrobial 
misuse leads not only to poor patient outcome, unnecessary 
adverse reactions and wasted resources, but also to 
emerging resistance of bacteria to antimicrobials. 
Antimicrobials can also be very expensive, and in most 
facilities they constitute a major portion of the drug budget. 
The phenomenon of resistance is seen not only in bacteria 
and mycobacteria (multidrug resistant TB, for example), but 
also in protozoal infections (resistance to chloroquine as an 
antimalarial) and viral infections (HIV and antiretrovirals). 
CONCLUSION  
All patient folders evaluated with regards to 
cellulitis,gynecological surgeries ,uti,lrti etc were found to 
meet the standard criteria appropriate for metronidazole 
use with respect to dose, and dose frequency. 
However, in the case of duration the evaluation was found to 
be largely inappropriate for all the justified indications. In 
addition, 34.81% of metronidazole use for unjustified 
indications was noted. This means that metronidazole has 
been deviated from standard treatment guidelines hence it 
facilitates the development of resistant strains to 
metronidazole and of no use in the near future, and it also 
effect the patient economically. 
RECOMMENDATION 
 Health care providers must be periodically updated with the 
national standard treatment guidelines. It is further 
recommended that the hospital’s management attention be 
drawn to the draw backs observed regarding the 
inappropriate use and duration of metronidazole, so that 
specific interventions could be initiated to improve its use 
for excellent outcomes. Following the implementation of the 
interventions, another DUE should be conducted to 
determine the level of adherence to the acceptable standards 
and its impact on patient outcomes. 
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ABBREVIATIONS USED  
ABC -always better control 
ADR  - adverse drug reaction 
ATC -anatomic therapeutic chemical codes 
CCU -critical care unit 
CDC -center for disease control  
DDD  -defined daily dosage 
DTC-drug and therapeutic commitee 
DUR -  drug utilization review 
DUE -drug utilization evaluation 
HCP -health care professionals 
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INRUD -international network for rational use of drugs 
ME - medication errors 
MUE - medication use evaluation 
PPMS-prescription pattern monitoring studies 
RUM -rational use of medicines 
STG’s-standard treatment guidelines 
VEN -vital essential nonessential 
WHO -world health organization 
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